Clinical trial NCT03774459: ANAVEX2-73 Study in Parkinson's Disease Dementia
Official title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Parkinsons Disease With Dementia
Lead sponsor: Anavex Life Sciences Corp.
Sponsor class: INDUSTRY
Collaborators: name: Anavex Germany GmbH
First posted: 2018-12-13
Enrollment: 132
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients with Parkinson's Disease with Dementia (PDD)

Detailed description: This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, three-arm, 14-week study in PD patients with dementia. The study includes a 2 week Screening / Baseline Observation Period and a 14-week Treatment Period (including a 2 week Titration Period), and a 2-week Safety Follow-Up Period

Eligibility criteria: Inclusion Criteria:

* Diagnosis of idiopathic Parkinson's disease (PD) consistent with the UK Parkinson's Disease Society Brain Bank diagnostic criteria.
* Diagnosis of probable PD dementia (PDD) according to the Movement Disorder Society Task Force clinical diagnostic criteria.
* Montreal Cognitive Assessment (MoCA) score of 13 to 23, inclusive, at Screening.
* Male or female and aged ≥ 50 years.
* Caregivers and subjects (or legal representative) must understand and have signed approved informed consent.
* Caregivers and subjects (or legal representative) must be able to understand study requirements and be willing to follow instructions.
* Stable regimen of anti-Parkinson's disease medications (including levodopa, dopamine agonists, MAO-B inhibitors, or the COMT inhibitor entacapone), which has been stable for at least 4 weeks prior to Baseline.
* Treatment with cholinesterase inhibitor (rivastigmine, donepezil and galantamine (Exelon®, Aricept®, or Reminyl®) will be permitted, provided the dose has been stable for a minimum of 8 weeks prior to randomization.
* Subjects with history of depression on antidepressant medications will be allowed if depression is controlled and they have been on a stable daily dose of the antidepressant for ≥8 weeks before Baseline.
* Contraception:

  * Women of childbearing potential must use an acceptable method of contraception starting 4 weeks prior to study drug administration and for a minimum of 4 weeks after study completion. Otherwise, women must be postmenopausal (at least one year absence of vaginal bleeding or spotting) as confirmed by FSH greater than or equal to 40 mIU/mL or 40 IU/L or be surgically sterile.
  * Men with a potentially fertile partner must have had a vasectomy or be willing to use an acceptable method of contraception for the duration of the study and for 3 months after study drug discontinuation.

Exclusion Criteria:

* History of any significant neurologic or psychiatric disorder other than PD that can contribute to cognitive impairment.
* Any other condition or clinically significant abnormal findings like severe co-morbidities e.g. history of stroke, poor kidney or liver function on the physical or neurological examination, medical and psychiatric history, at screening or at baseline that, in the opinion of the Investigator, would make the subject unsuitable for the study.
* Potential symptomatic causes of cognitive impairment including but not limited to

  1. abnormal thyroid function test at screening (TSH)
  2. abnormal B12 level at screening
  3. MRI findings (by history) pointing to a potential symptomatic cause of cognitive dysfunction, including significant vascular changes, or communicating hydrocephalus.
* Treatment with memantine or amantadine. If appropriate the drugs can be discontinued for a minimum of 4 weeks prior to randomization.
* Use of over the counter (OTC) or prescription medication for sleep on 2 or more occasions per week (less than that is allowed).
* History of depression as measured by Beck Depression Inventory score \>17 at screening.
* Treatment with any other investigational drug or device within 4 weeks prior to screening.
* Smoking \> 1 pack of cigarettes per day (as assessed for the 4 weeks prior to screening).
* Women who are pregnant or lactating.
* Known allergy or sensitivity to ANAVEX2-73 or any of its components.
* Suicidal ideation on the Columbia Suicide Severity Rating Scale (C-SSRS) of type 4 or type 5, or any suicidal behavior, in the past 6 months. Type 4 indicates active suicidal ideation with some intent to act, without a specific plan. Type 5 indicates active suicidal ideation with a specific plan and intent.
* Use of centrally acting anticholinergic drugs during the 4 weeks before randomization.
* Medications used for overactive bladder will be allowed provided that the regimen has been stable 4 weeks prior to randomization.
* Treatment with any dopamine receptor blocking medications with the exception of low dose quetiapine (≤50 mg/day). Pimavanserin (≤34 mg/day) will be allowed.
* History of neurosurgical intervention (e.g., deep brain stimulation) for PD.
* Unpredictable motor fluctuations that would interfere with administering cognitive assessments in the ON state.

Primary outcomes:
measure: Cognitive Drug Research (CDR) Computerized Assessment System Continuity of Attention
timeFrame: 14 weeks
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
timeFrame: 14 weeks
Secondary outcomes:
measure: MDS-UPDRS Part III Total Score (Motor Scores)
timeFrame: 14 weeks
measure: SDS-CL-25
timeFrame: 14 weeks
Other outcomes:
Locations:
city: Macquarie Park
country: Australia
facility: KaRa MINDS
city: Malvern
country: Australia
facility: Hammond Health
city: Barakaldo
country: Spain
facility: Hospital Cruces Bilbao
city: Barcelona
country: Spain
facility: Hospital de la Santa Creu i Sant Pau
city: Barcelona
country: Spain
facility: Hospital Mutua Terrasa
city: Barcelona
country: Spain
facility: Hospital Universitario Vall d'Hebron
city: Burgos
country: Spain
facility: Hospital Universitario de Burgos
city: Cadiz
country: Spain
facility: Hospital Universitario Puerta del Mar
city: Coslada
country: Spain
facility: Hospital del Henares
city: Elche
country: Spain
facility: Hospital General Universitario de Elche
city: Ferrol
country: Spain
facility: Hospital Arquitecto Marcide
city: Girona
country: Spain
facility: Hospital Santa Caterina
city: Madrid
country: Spain
facility: Clinica Ruber Internacional
city: Madrid
country: Spain
facility: Clínica Universidad de Navarra (CUN) - Sede Madrid- Servicio de Neurología -
city: Madrid
country: Spain
facility: Hospital Clínico San Carlos
city: Madrid
country: Spain
facility: Hospital de La Princesa
city: Madrid
country: Spain
facility: Hospital General Universitario Gregorio Marañón
city: Madrid
country: Spain
facility: Hospital Infanta Leónor
city: Madrid
country: Spain
facility: Hospital Universitario Puerta de Hierro
city: Madrid
country: Spain
facility: Hospital Universitario Ramón y Cajal
city: Móstoles
country: Spain
facility: Hospital HM Puerta del Sur
city: Oviedo
country: Spain
facility: Hospital Universitario Central de Asturias (HUCA)
city: Pamplona
country: Spain
facility: Clínica Universidad de Navarra (CUN)
city: Santiago de Compostela
country: Spain
facility: Hospital de Santiago de Compostela
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen del Rocío
Study officials:
References: